Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer (Q33875597)

24755199

29 July 2017

title

Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer (English)

1 reference

29 July 2017

1 reference

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Guillermo Armaiz-Pena

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

15

Joseph M DeSimone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

16

Anil K Sood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

12

J Christopher Luft

1 reference

31 May 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

10

Tojan B Rahhal

1 reference

31 May 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

Kshipra M Gharpure

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Kevin S Chu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Charles J Bowerman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Takahito Miyake

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sunila Pradeep

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Selanere L Mangala

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Hee-Dong Han

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sherry Y Wu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Mary E Napier

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Gabriel Lopez-Berestein

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

1 reference

22 April 2014

1 reference

24755199

Molecular Cancer Therapeutics

29 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1750-1757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.

31 May 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic chemotherapy for cancer treatment: a decade of clinical studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Regulation of tumor angiogenesis by EZH2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

The anti-angiogenic basis of metronomic chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Ovarian cancer: strategies for overcoming resistance to chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic scheduling: the future of chemotherapy?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

What Is the Evidence That Tumors Are Angiogenesis Dependent?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24755199

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-13-0930

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

24755199

1 reference